Asthma therapy may help ease symptoms of MuSK-positive MG
Treatment with an oral version of salbutamol, the active ingredient of medications used for asthma and other respiratory conditions, may…
Articles by Marisa Wexler, MS
Dianthus launches Phase 2 trial to test DNTH103 in generalized MG
Dianthus Therapeutics is launching a Phase 2 clinical trial to test its experimental therapy, DNTH103, in people with…
Use of under-the-skin efgartigimod now approved for gMG in Japan
An under-the-skin or subcutaneous injection formulation of efgartigimod has been approved in Japan for use by adults with generalized…
Descartes-08 shown to reduce gMG disease severity up to 1 year in trial
Treatment with the experimental cell therapy Descartes-08 led to reductions in disease severity that were sustained out to one year…
Cell therapy KYV-101 put on FDA fast track as MG treatment
KYV-101, an experimental cell therapy for myasthenia gravis (MG) in development by Kyverna Therapeutics, has been granted fast…
New generic version of Mestinon as oral syrup available in U.S.
A new generic formulation of pyridostigmine bromide — a muscle-strengthening medication sold under the brand name Mestinon — is…
Under-the-skin Vyvgart approved in Europe for AChR-positive gMG
A new under-the-skin injectable formulation of Vyvgart (efgartigimod alfa) has been approved by the European Commission for adults with…
Kyverna to conduct Phase 2 trial of cell therapy KYV-101 in MG
The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application from Kyverna Therapeutics, giving…
Cabaletta cleared to launch Phase 1/2 trial of cell therapy for gMG
The U.S. Food and Drug Administration (FDA) has given Cabaletta Bio the go-ahead to launch a Phase 1/2 clinical…
Zilucoplan, now Zilbrysq, approved by FDA for AChR-positive gMG
The U.S. Food and Drug Administration (FDA) has approved zilucoplan, a once-daily injection therapy to now be marketed under…